LONG-TERM REABSORBABLE SUBCUTANEOUS IMPLANT WITH PROLONGED RELEASE OF PRE-CONCENTRATED PHARMACOLOGICALLY ACTIVE SUBSTANCE IN POLYMER FOR TREATING CHRONIC ADRENAL INSUFFICIENCY OR HYPOCORTICISM Russian patent published in 2024 - IPC A61K31/573 A61K47/30 A61P5/14 

Abstract RU 2831450 C1

FIELD: medicine.

SUBSTANCE: group of inventions relates to a long-term degradable subcutaneous implant with a prolonged release of a pre-concentrated pharmaceutically active substance in a polymer for the treatment of chronic adrenal insufficiency or hypocortisolism, which is characterized by the fact that the biodegradable hydrocortisone implant remains in the polymer matrix, while the biodegradable implant contains from 5 mg to 250 mg of hydrocortisone uniformly distributed in said bioabsorbable polymer matrix, wherein composition of polymer matrix is from 1% to 20% of biodegradable polymer with respect to weight of hydrocortisone, and also relates to a long-term degradable subcutaneous implant with a pre-concentrated pharmaceutically active substance in a polymer for the treatment of chronic adrenal insufficiency or hypocortisolism, which is characterized by that the implant is presented in a non-biodegradable or non-biodegradable form (2), having central core (2.1) formed by a polymer matrix in a percentage ratio of 1% to 20% with respect to the weight of the drug, in this case, from 5 mg to 250 mg of hydrocortisone, the nucleus is surrounded by a non-degradable polymer membrane (2.2).

EFFECT: group of inventions provides reducing inflammation and pain, as well as restoring the patient’s circadian cycle in order to restore the physiology of life-wakefulness during the day and sleep at night.

8 cl, 4 dwg

Similar patents RU2831450C1

Title Year Author Number
LONG-ACTING CONTROLLED-RELEASE SUBCUTANEOUS POLYMER IMPLANT OF PHARMACOLOGICAL PRE-CONCENTRATED SUBSTANCE FOR TREATMENT OF ERECTILE DYSFUNCTION AND BENIGN PROSTATIC HYPERPLASIA 2020
  • Luiz Perakki Edson
RU2822514C1
HYDROCORTISONE COMPOSITION WITH CONTROLLED RELEASE 2013
  • Khyutan Khip
  • Ross Richard
  • Uitaker Martin
RU2619869C2
CFR RECEPTOR ANTAGONISTS FOR TREATMENT OF CONGENITAL ADRENAL HYPERPLASIA 2015
  • Grigoriadis, Dimitri, E.
RU2812318C2
CFR RECEPTOR ANTAGONISTS FOR TREATING CONGENITAL ADRENAL HYPERPLASIA 2015
  • Grigoriadis Dimitri E.
RU2718918C2
COMPOSITION COMPRISING HYDROCORTISONE 2014
  • Huatan Hiep
  • Ross Richard
  • Whitaker Martin
  • Poellinger Norbert
  • Grave Annette
RU2664678C2
COMBINATION OF SOMATOSTATIN ANALOGUES WITH 11β-HYDROXYLASE INHIBITORS 2013
  • Gerikke Germo Khans
  • Shmid Kherbert Anton
  • Maldonado Lutomirski Mario Roberto
  • Li Li
RU2663455C2
CORTICOSTEROIDS FOR JOINT PAIN TREATMENT 2011
  • Bodik Nil
  • Blenks Robert S.
  • Kumar Andzhali
  • Klejman Majkl D.
  • Moran Mark
RU2642279C2
APPLICATION OF AGENT WITH MODIFYING PROPERTIES IN RELATION TO HORMONES OF ADRENAL GLANDS 2011
  • Tsiin Syuj
  • Geri Ksander
  • Erik Meredit
  • Loren G. Monovich
  • Zhyulen Papijon
  • Kristof Shumakher
RU2598708C2
IMPLANTABLE NALTREXONE TABLETS 2016
  • Kunal Saksena
  • Yambaiakh Kamtkhimatkh
  • Brijmokhan Sharma
RU2620254C1
METHOD OF INDIVIDUAL RECOVERY OF FUNCTIONAL ACTIVITY OF ADRENAL CORTEX IN PATIENTS WITH SOMATIC DISEASES WITH LONG HISTORY OF GLUCOCORTICOSTEROID THERAPY 2010
  • Tishenina Raisa Stepanovna
  • Stotskaja Tat'Jana Vasil'Evna
  • Molochkov Vladimir Alekseevich
  • Jankovskaja Nina Igorevna
  • Borodina Elena Georgievna
RU2439563C1

RU 2 831 450 C1

Authors

Luiz Perakki Edson

Dates

2024-12-09Published

2020-08-31Filed